Connection

Michael Zile to Time Factors

Back to Details
This is a "connection" page, showing publications Michael Zile has written about Time Factors.
Michael Zile
Connection Strength
1.125
Time Factors
  1. Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord. 2021 03 26; 21(1):155.
    View in: PubMed
    Score: 0.102
  2. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. Semin Thorac Cardiovasc Surg. 2016 Summer; 28(2):320-328.
    View in: PubMed
    Score: 0.073
  3. Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance. Circ Heart Fail. 2016 Jan; 9(1):e002543.
    View in: PubMed
    Score: 0.071
  4. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail. 2011 Feb; 17(2):167-78.
    View in: PubMed
    Score: 0.050
  5. Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg. 2002 Apr; 123(4):707-14.
    View in: PubMed
    Score: 0.027
  6. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 08 03; 10(15):e019545.
    View in: PubMed
    Score: 0.026
  7. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
    View in: PubMed
    Score: 0.025
  8. Loop Diuretic Prescription and 30-Day?Outcomes in Older Patients With?Heart?Failure. J Am Coll Cardiol. 2020 08 11; 76(6):669-679.
    View in: PubMed
    Score: 0.024
  9. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 02; 13(2):e006541.
    View in: PubMed
    Score: 0.024
  10. Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. Circ Heart Fail. 2020 02; 13(2):e006696.
    View in: PubMed
    Score: 0.024
  11. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020 04; 222:183-190.
    View in: PubMed
    Score: 0.024
  12. Echocardiographic Features of Patients?With Heart?Failure and Preserved?Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 12 10; 74(23):2858-2873.
    View in: PubMed
    Score: 0.023
  13. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 12; 12(12):e006539.
    View in: PubMed
    Score: 0.023
  14. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. J Am Heart Assoc. 2019 09 03; 8(17):e013114.
    View in: PubMed
    Score: 0.023
  15. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018 12 01; 3(12):1226-1231.
    View in: PubMed
    Score: 0.022
  16. Initial retinoid requirement for early avian development coincides with retinoid receptor coexpression in the precardiac fields and induction of normal cardiovascular development. Dev Dyn. 1998 Oct; 213(2):188-98.
    View in: PubMed
    Score: 0.021
  17. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018 12; 20(12):1701-1709.
    View in: PubMed
    Score: 0.021
  18. Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2018 10 01; 315(4):H958-H967.
    View in: PubMed
    Score: 0.021
  19. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov; 10(11).
    View in: PubMed
    Score: 0.020
  20. Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade. Am J Physiol Renal Physiol. 2018 02 01; 314(2):F210-F218.
    View in: PubMed
    Score: 0.020
  21. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.020
  22. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 11 29; 134(22):1785-1787.
    View in: PubMed
    Score: 0.019
  23. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Circ Heart Fail. 2016 09; 9(9).
    View in: PubMed
    Score: 0.019
  24. Influence of Sacubitril/Valsartan (LCZ696)?on?30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016 07 19; 68(3):241-248.
    View in: PubMed
    Score: 0.018
  25. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2017 Jan; 23(1):20-28.
    View in: PubMed
    Score: 0.018
  26. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 06; 9(6).
    View in: PubMed
    Score: 0.018
  27. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 07; 133(23):2254-62.
    View in: PubMed
    Score: 0.018
  28. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Apr; 9(4):e002763.
    View in: PubMed
    Score: 0.018
  29. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.
    View in: PubMed
    Score: 0.018
  30. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.018
  31. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail. 2015 Jul; 8(4):717-24.
    View in: PubMed
    Score: 0.017
  32. Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. Circ Heart Fail. 2015 Jul; 8(4):733-40.
    View in: PubMed
    Score: 0.017
  33. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014 Sep; 7(5):740-51.
    View in: PubMed
    Score: 0.016
  34. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. JACC Cardiovasc Imaging. 2014 Sep; 7(9):870-8.
    View in: PubMed
    Score: 0.016
  35. Effects of chronic mitral regurgitation on diastolic function in isolated cardiocytes. Circ Res. 1993 May; 72(5):1110-23.
    View in: PubMed
    Score: 0.015
  36. Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing. Am J Physiol Heart Circ Physiol. 2012 Nov 01; 303(9):H1128-34.
    View in: PubMed
    Score: 0.014
  37. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012 Sep 01; 5(5):571-8.
    View in: PubMed
    Score: 0.014
  38. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf. 2012 Mar 01; 35(3):233-44.
    View in: PubMed
    Score: 0.014
  39. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012 Mar 01; 5(2):217-25.
    View in: PubMed
    Score: 0.014
  40. Chronic aortic and mitral regurgitation. Choosing the optimal time for surgical correction. Cardiol Clin. 1991 May; 9(2):239-53.
    View in: PubMed
    Score: 0.013
  41. Left ventricular diastolic dysfunction limits use of maximum systolic elastance as an index of contractile function. Circulation. 1991 Feb; 83(2):674-80.
    View in: PubMed
    Score: 0.013
  42. Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up. Am J Cardiol. 2011 Jan 15; 107(2):321-4.
    View in: PubMed
    Score: 0.012
  43. Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol. 2009 Nov; 297(5):H1744-51.
    View in: PubMed
    Score: 0.011
  44. In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. Am J Physiol Heart Circ Physiol. 2008 Jul; 295(1):H314-26.
    View in: PubMed
    Score: 0.010
  45. Selective translation of mRNAs in the left ventricular myocardium of the mouse in response to acute pressure overload. J Mol Cell Cardiol. 2008 Jan; 44(1):69-75.
    View in: PubMed
    Score: 0.010
  46. Right ventricular pacing reduces the rate of left ventricular relaxation and filling. J Am Coll Cardiol. 1987 Sep; 10(3):702-9.
    View in: PubMed
    Score: 0.010
  47. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant. 2007 Feb; 26(2):145-51.
    View in: PubMed
    Score: 0.010
  48. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006 Mar; 131(3):679-85.
    View in: PubMed
    Score: 0.009
  49. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol. 2005 Jan; 288(1):H149-58.
    View in: PubMed
    Score: 0.008
  50. Integrin activation and focal complex formation in cardiac hypertrophy. J Biol Chem. 2000 Nov 10; 275(45):35624-30.
    View in: PubMed
    Score: 0.006
  51. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther. 1999 Nov; 291(2):799-811.
    View in: PubMed
    Score: 0.006
  52. Mechanisms of cardiac hypertrophy in canine volume overload. Am J Physiol. 1998 Jul; 275(1 Pt 2):H65-74.
    View in: PubMed
    Score: 0.005
  53. Growth effects of electrically stimulated contraction on adult feline cardiocytes in primary culture. Am J Physiol. 1995 Jun; 268(6 Pt 2):H2495-504.
    View in: PubMed
    Score: 0.004
  54. Load effects on gene expression during cardiac hypertrophy. J Mol Cell Cardiol. 1995 Jan; 27(1):485-99.
    View in: PubMed
    Score: 0.004
  55. Coronary blood flow after the regression of pressure-overload left ventricular hypertrophy. Circ Res. 1992 Dec; 71(6):1472-81.
    View in: PubMed
    Score: 0.004
  56. Left ventricular mechanics and myocyte function after correction of experimental chronic mitral regurgitation by combined mitral valve replacement and preservation of the native mitral valve apparatus. Circulation. 1992 Nov; 86(5 Suppl):II16-25.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.